Medical Device Advertising and Intended-Use Compliance in Pakistan

1. Key takeaways

The constraints on device promotion in Pakistan can be derived from two provisions taken together. First, Rule 14(6) requires the label and the prescribing information to be consistent with the approved version in the country of origin or the reference country; second, the object of enlistment or registration is the product under a specific intended use. Combining the two yields the operative conclusion: promotional content must not exceed the intended-use scope that has been enlisted or registered — anything beyond that scope has no approval basis and directly violates the label consistency requirement. This is a tighter rule than many companies expect. Promotion is not regulated here by a general anti-misleading-advertising principle applied after the fact; it is bounded by a document, the approved file, whose text can be checked line by line. Whatever the certificate says the product is for, the promotion may say the same thing and no more. Material that drifts beyond the registered intended use is not merely risky in an abstract sense — it contradicts a specific, verifiable regulatory requirement. The practical read-across is also worth noting: if promotion must stay within the certificate, then the certificate text itself becomes the boundary document for the marketing department, which means marketing and regulatory need to share the same source file rather than working from paraphrases of it.

2. Legal basis

The provisions relevant to promotional compliance are set out below: the label and prescribing information consistency rule, the local representative labelling rule, the certificate provisions, the cancellation power, and the classification principles from which the intended-use linkage ultimately derives.

3. Expert insights

Insight one: the risk class is derived from the intended use, so changing the use means changing the classification. Classification in Pakistan depends on the intended use, the duration of contact, invasiveness, whether the device is active, and the consequences of failure. Once a new indication or a new use appears in promotional material, the product has in substance moved away from the basis on which it was registered. This is why a seemingly innocent marketing phrase can carry regulatory weight far beyond its size: the phrase effectively proposes a reclassification that no one has applied for. The correct route for a genuinely new intended use is a change filing at the registration level, not a soft expansion of the advertising copy while the certificate stands still. Companies that internalise this distinction stop treating classification as paperwork filed once at entry and start treating it as the live boundary of their commercial claims.

Insight two: Rule 14(6) makes the approved version a hard standard that can be checked. A reviewer can place the Pakistani label directly beside the approval documents of the reference country or country of origin and compare them. This is considerably more operational than principle-based statements such as a prohibition on false advertising, and it is also the line that companies cross most easily. Principle-based rules require a judgement about whether a claim is misleading; document-based rules require only a comparison of texts. When the comparison is that simple, the reviewer’s discretion is small and the company’s margin for creative deviation is equally small. Promotional governance should therefore be built around document control, not around the hope that reviewers will read claims generously. In practice this means every claim in a brochure or on a website can be traced to a sentence in the approved file, and any claim that cannot be traced is deleted or filed for approval before publication.

Insight three: cancellation or suspension is the backstop consequence. Rule 15(4) makes clear that the certificate may be cancelled or suspended within its five-year term. A promotion violation does not necessarily end with a fine; it can act directly on the status of the certificate itself. This changes the calculus of compliance substantially. A marketing manager weighing the benefit of a bolder claim against a nominal penalty is doing the wrong arithmetic, because the real exposure is the market authorisation on which every unit of Pakistan revenue depends. The consequence is also disproportionate by design: the authority treats the certificate as conditional on lawful conduct throughout its life, not only at the moment of grant.

4. Practical recommendations

When GRZAN performs a compliance pre-review of promotional material for Pakistan, it checks the material against three references: the product name and intended use as stated on the enlistment or registration certificate, the label and prescribing information approved in the country of origin or the reference country, and the local representative information required under Rule 24(b). The material is released only when all three correspond. Chinese-language source materials frequently contain indication-expansion statements, and these must be removed before the material enters Pakistan, because they are precisely the kind of content that exceeds the registered intended use. The pre-review is quick when the three references are assembled in advance, which is an argument for keeping the certificate, the approved artwork and the local representative details in one accessible file rather than spread across departments.

5. Verification checklist

• □ Promotional content does not exceed the enlisted / registered intended use
• □ Material statements are consistent with the content stated on the certificate
• □ Label and prescribing information have been checked against the approved version (Rule 14(6))
• □ Material carries the local representative name and address (Rule 24(b))
• □ The impact of violations on certificate survival has been assessed (Rule 15(4))

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com